It’s only fair to share… WO-2018001353, APREMILAST, NEW PATENT, ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (WO2018001353) METHOD FOR PREPARING APREMILAST ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD DU, Xiaoqiu; (CN). ZHOU, Lianchao; (CN). LIU, Jiegen; (CN) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018001353&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=FullText EN)Method one: (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine N-acetyl-L-leucine salt of formula II is reacted with 3-acetylaminophthalic anhydride of formula III …
(2R,3S,4R,5R)-1-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2,3,4,5,6-pentahydroxyhexan-1-one
It’s only fair to share… CAS 1672658-93-3 C24 H25 F O6 S, 460.52 D-Glucopyranose, 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]- CAS 1809403-04-0 C24 H25 F O6 S, 460.52 D-Glucose, 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]- WO2017/93949 (2R,3S,4R,5R)-1-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2,3,4,5,6-pentahydroxyhexan-1-one 12 From the FT-IR spectra of 12 contain a signal at 1674 cm–1, this signal is strongly indicative of a carbonyl ketone being present in 12 In 13C NMR and HMBC correlations spectra, the chemical shift at 199.75 ppm …
ELAGOLIX
It’s only fair to share… ELAGOLIX Molecular FormulaC32H30F5N3O5 Average mass631.590 Da NBI56418, ABT 620 UNII:5B2546MB5Z 4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid 834153-87-6 FREE ACID SODIUM SALT 832720-36-2 Acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-[2-fluoro-6-(trifluorométhyl)benzyl]-4-méthyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phényléthyl}amino)butanoïque Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]- GNRH antagonist, Endometriosis Endometriosis PREREGISTERED Phase III Uterine leiomyoma WO2001055119A2, Inventors Yun-Fei Zhu, Chen Chen, Fabio C. Tucci, Zhiqiang Guo, Timothy D. Gross, Martin Rowbottom, R. Scott Struthers, Applicant Neurocrine Biosciences, Inc. WO 2005007165 PDT PATENT …
Empesertib , BAY 1161909
It’s only fair to share… Empesertib , BAY 1161909, Mps1-IN-5, (-)-BAY-1161909 CAS 1443763-60-7 Chemical Formula: C29H26FN5O4S Molecular Weight: 559.6164 [a]D20 : -78.9° (in DMSO). WO 2014198647 UNII-02Y3Z2756M (αR)-4-Fluoro-N-[4-[2-[[2-methoxy-4-(methylsulfonyl)phenyl]amino][1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]-α-methylbenzeneacetamide (R)-2-(4-fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)propanamide (2R)-2-(4-Fluorophenyl)-N-(4-(2-((4-(methanesulfonyl)-2-methoxyphenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide Benzeneacetamide, 4-fluoro-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)-alpha-methyl-, (alphaR)- PHASE 1, BAYER, CANCER PRODUCT PATENT, WO2013087579, https://www.google.com/patents/WO2013087579A1 SYNTHESIS, WO 2014198647 Analytical UPLC-MS was performed as follows: Method A: System: UPLC Acquity (Waters) with PDA Detector und Waters …
Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer
It’s only fair to share… Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer On November 23, 2017, Biocon India’s premier Biopharmaceuticals Company announced that it has launched KRABEVA®, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, …
Pexidartinib, New Patent, WO 2017215521, Crystal Pharmatech Co Ltd
It’s only fair to share… Pexidartinib, New Patent, WO, 2017215521, Crystal Pharmatech Co Ltd (WO2017215521) PLX3397 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017215521 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD INVENTORS CHEN, Minhua; (CN). ZHANG, Yanfeng; (CN). ZOU, Po; (CN). ZHANG, Xiaoyu; (CN) Novel crystalline forms of PLX3397 hydrochloride (designated as Forms CS2 and …
Psilocybin, псилоцибин , بسيلوسيبين , 赛洛西宾 ,
It’s only fair to share… Psilocybin Molecular FormulaC12H17N2O4P Average mass284.248 Da 4-22-00-05665 (Beilstein Handbook Reference) [Beilstein] 520-52-5 [RN] 1H-Indol-4-ol, 3-[2-(dimethylamino)ethyl]-, dihydrogen phosphate (ester) 208-294-4 [EINECS] 3-[2-(Dimethylamino)ethyl]-1H-indol-4-ol Dihydrogen Phosphate Ester псилоцибин [Russian] [INN] بسيلوسيبين [Arabic] [INN] 赛洛西宾 [Chinese] [INN] NM 3150000 O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine P-7825 PDSP1_001391 UNII-2RV7212BP0 MP 220-228 deg C, O’Neil, M.J. (ed.). The Merck Index – An Encyclopedia of Chemicals, Drugs, and …
ALCAFTADINE, WO 2017211246, NEW PATENT, SHENZHEN TARGETRX, INC.
It’s only fair to share… Alcaftadine NEW PATENT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017211246&redirectedID=true WO-2017211246, SHENZHEN TARGETRX, INC. SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF WANG, Yihan; (CN). XING, Qingfeng; (CN) Novel deuterated analogs of substituted fused imidazole cyclic compounds, particularly alcaftadine are histamine H1-receptor antagonists and mast cell stabilizers, useful for treating allergy and nasal congestion. The present …
Benzyl (5-methylpyrazin-2-yl)carbamate
It’s only fair to share… 2-(Cbz-Amino)-5-methylpyrazine Molecular Formula: C13H13N3O2 Molecular Weight: 243.266 g/mol Benzyl (5-methylpyrazin-2-yl)carbamate CAS 1033418-57-3 Mp 191.4 °C. IR 1719, 1567, 1353, 1226, 1054, 759, 744, 706 cm–1. 1H NMR (DMSO-d6, 500 MHz) 10.45 (br, 1H), 8.93 (s, 1H), 8.20 (s, 1H), 7.42–7.32 (m, 5H), 5.18 (s, 2H), 2.41 (s, 3H). 13C NMR (DMSO-d6, …
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
It’s only fair to share… FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an …